openPR Logo
Press release

Chronic Lymphocytic Leukemia Treatment Market to Expand at a Healthy CAGR of 19% by 2023

01-13-2022 08:55 AM CET | Health & Medicine

Press release from: market research future

Chronic Lymphocytic Leukemia Treatment Market to Expand at

Market Scenario
As per the data experts at Market Research Future (MRFR), the chronic lymphocytic leukemia treatment market was worth USD 7.9 Billion in 2017. Additionally, the market is expected to expand at a growth rate of 19% over the forecast period (2018-2023).

Market Drivers and Key Challenges
Chronic lymphocytic leukemia is considered to be one of the most common types of leukemia in adults. This type of cancer involves the development of lymphocytes, which are white blood cells, within the bone marrow. The lymphocytic leukemia cells are generally present in the lymph nodes along with various other tissues. There are two primary types of chronic lymphocytic leukemia, wherein one grows slowly, and the other is considered fatal. In general, one does not experience any symptoms due to chronic lymphocytic leukemia for a long period. However, the symptoms usually noted include fatigue, easy bruising, and swollen lymph nodes.

Generally, the most popular form of treatment for CLL is chemotherapy, whereas stem-cell transplant is for rare cases. An article published by Apollo Hospitals states that in India, roughly one million cases of chronic lymphocytic leukemia are diagnosed annually. As per the cancer statistics, 1 in every 155 men and 1 in every 260 women get affected with CLL in their lifetime, in the United Kingdom (U.K). The boost in cancer cases around the world, innovations in drug therapy, quick regulatory approval processes, and vigorous pipeline of drugs for chronic lymphocytic leukemia treatment are additional factors substantiating the growth of the chronic lymphocytic leukemia market.

Having said that, the stunted level of awareness with regard to symptoms is expected to retard the market growth in the forthcoming years. However, growing research & development activities coupled with continuous technological developments in the field is presumed to augment the market growth to a large extent.

Request Free Sample Report at: https://www.marketresearchfuture.com/sample_request/6900

Market Segmentation
The global chronic lymphocytic leukemia treatment market has been segmented on the basis of type, treatment, and end user.
The market, in terms of the type, has been considered for indolent CLL and aggressive CLL.
The market, treatment-wise, can be broken down into chemotherapy, targeted drug therapy, immunotherapy, and bone marrow transplant.
The end users in the global market are hospitals & clinics, diagnostic laboratories, research institutes, and others.

Prominent Players
The prominent vendors within the worldwide chronic lymphocytic leukemia treatment market include Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Genmab A/S, TG Therapeutics, Inc., Ziopharm Oncology, F. Hoffmann-La Roche Ltd, AbbVie Inc., Genentech, Inc., Gilead, Genzyme Corporation, ONO PHARMACEUTICAL CO., LTD., GlaxoSmithKline plc, CELGENE CORPORATION, Inc., Johnson & Johnson Services, Inc., and others.

Regional Insight
The chronic lymphocytic leukemia treatment market is set to expand in the region of Europe, Asia Pacific, America, and the Middle East & Africa during the assessment period.

Following a meticulous analysis of the global trends, the Americas has been identified as the leading region in the chronic lymphocytic leukemia treatment market. The increasing prevalence of leukemia, as well as the presence of prominent vendors within the region, are the main factors responsible for the strong performance of the market. In 2018, a report published by the Leukemia & Lymphoma Society stated that every 3 minutes, an individual in the United States (US) gets diagnosed with blood cancer or leukemia.
Europe has managed to seize the second largest share of the global chronic lymphocytic leukemia treatment market. Sound healthcare infrastructure, massive healthcare spending, high awareness levels with regard to relapse of Chronic Lymphocytic Leukemia (CLL) as well as related treatments, availability of reimbursement policies, use of advanced healthcare tools and the growing adoption rate of latest techniques in practice are few lucrative factors steering the CLL treatment market towards greater heights.

With the hike in the research and development activities and the presence of profitable small markets like India, Japan, China, Australia, Republic of Korea, the Asia Pacific market is expected to expand further in the subsequent years. The region is also predicted to grow at the fastest rate, backed by factors like the growing prevalence of leukemia combined with the consequently surging demand for treatment of CLL in the region. The 2017 report furnished by the World Health Organization (WHO) suggests that at least 8,904 leukemia deaths have been reported in Japan that year, indicating the rising number of cases within the region.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/chronic-lymphocytic-leukemia-treatment-market-6900

The most abysmal performance has been showcased by the Middle East & Africa, having managed to acquire the least share of the worldwide market. However, the lukewarm growth of the market points towards better prospects in the future, owing to the expanding healthcare infrastructure.

Industry Developments
• May 2019: Venetoclax (Venclexta, AbbVie, and Genentech) along with Obinutuzumab (Gazyva, Genentech) has been granted FDA approval for untreated chronic lymphocytic leukemia (CLL). Venclexta, as well as Gazyva, is considered to be the only chemotherapy-free option for providing favorable responses to aid the patients in living longer and curbing the progression of CLL as well.

Browse Related Reports at:

https://www.marketresearchfuture.com/reports/formulation-development-outsourcing-market-10387

https://www.marketresearchfuture.com/reports/sleep-apnea-devices-market-2061

https://www.marketresearchfuture.com/reports/medical-ceramics-market-5729

Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
Email: sales@marketresearchfuture.com

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Lymphocytic Leukemia Treatment Market to Expand at a Healthy CAGR of 19% by 2023 here

News-ID: 2525776 • Views: 357

More Releases from market research future

Corporate Wellness Market Research Report, Industry Growth, Business Share, Size …
Market Highlights: The Global Corporate Wellness Market will reach value of USD 93.0 Billion in 2028 and is projected to grow at a CAGR of 7.0% over the forecast period. Corporate wellness programs are health promotion activities designed & conducted by corporate employers to support employees to understand their health risks, pursue healthy behavior at the workplace, and decrease the expenditure on healthcare. Currently, these programs are increasingly conducted by corporates
Facial Injectors Market Research Report, Industry Growth, Business Share, Size, …
Facial Injectors Market Information By Type (Dermal Fillers/Injectable Implants, Hyaluronic Acid, Synthetic Fillers, Collagen Fillers, Anti-Aging/Anti-Wrinkle Injections, Botulinum Toxin A, Poly-L-Lactic Acid (PLLA) Microparticles), By Application (Facial Line Correction Treatment, Face-Lift, Lip Treatments), By End-User (Dermatology Clinics & Cosmetic Centers, Hospitals), By Region (Americas, Europe, Asia Pacific and The Middle East & Africa) – till 2027 Market Scenario Market Research Future (MRFR) speculates that the Global Facial Injectors Market is predicted to
Healthcare Cold Chain Logistics Market Global Demand, Stock, Strategy, Size, Bus …
Healthcare Cold Chain Logistics Market Information by Product type (Biopharmaceuticals, Vaccines, Clinical Trial Materials and Others), Services (Storage, Transportation, Packaging and Others), Storage Techniques (Electrical refrigeration, Dry Ice, Gel Packs, Liquid nitrogen and Others), By Region (North America, Europe, Asia Pacific, The Middle East & Africa (MEA) and Latin America) – Global Forecast by 2027 Healthcare Cold Chain Logistics Market – Overview The progress in the pharmaceutical sector has amplified the reliance
Ophthalmic Drugs Market Research Report, Industry Growth, Business Share, Size, …
“Global Ophthalmic Drugs Market” Report of Market Research Future (MRFR)’s Explores Scope of the Study as Research Objective, Assumptions and Limitations in-depth. The report gives Market Dynamics by Major Drivers, Restraints, Opportunities and Challenges. Market Scenario A number of factors such as rising prevalence of eye diseases, growing awareness, huge research funding in ophthalmology, unmet medical needs, rising competition among market players, improving regulatory framework, aging population, and increasing government assistance, are

All 5 Releases


More Releases for CLL

Global Chronic Lymphocytic Leukemia (CLL) Drugs Market US$ 5.9 Billion by 2021
The global chronic lymphocytic leukemia (CLL) drugs market expected to reach US$ 5.9 billion by 2021, growing at CAGR 13.6% over the forecast period 2017-2021. Chronic lymphocytic leukemia is one of the most common forms of leukemia. American Cancer Society estimates about 20,110 new cases of chronic lymphocytic leukemia in the United States for 2017. CLL accounts for about one-quarter of the new cases of leukemia. The main treatments used
2017 Research Report on Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2
"Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- '
Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review H1 – 2017: Ma …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries
Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review H1 – 2017: Ma …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted
Relapsed Chronic Lymphocytic Leukemia (CLL) Pipeline Insight and Therapeutic Ass …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Relapsed Chronic Lymphocytic Leukemia (CLL)-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Relapsed Chronic Lymphocytic Leukemia (CLL). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Relapsed Chronic Lymphocytic
Therapeutics Development of Chronic Lymphocytic Leukemia (CLL) - Pipeline Review …
ResearchMoz added Latest Research Report titled " Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017 " to it's Large Report database. Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape. Chronic lymphocytic leukemia (CLL) is a type of cancer that starts